CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)

PHASE3CompletedINTERVENTIONAL

Enrollment

526

Participants

Timeline

Start Date

May 31, 2005

Study Completion Date

April 30, 2009

Conditions

CancerVenous Thromboembolism

Interventions

DRUG

Bemiparin

Bemiparin 3.500 IU/day for 28 days compared to 8 days

Trial Locations (4)

Lisbon

Timișoara

Saint Petersburg

Madrid

All Listed Sponsors

lead

Rovi Pharmaceuticals Laboratories

INDUSTRY

NCT00219973 - CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation) | Biotech Hunter | Biotech Hunter